Clinical Trial

A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this trial is to see if this investigational drug is safe for adult patients with melanoma that has spread to other parts of the body or cannot be removed by surgery. It will also see if this investigational drug can shrink melanoma tumors in the body. The main questions this study aims to answer are: * What are the side effects of this investigational drug? * What is the highest dose of this investigational drug that can be given safely? Participants will: * Take the investigational drug once every 6 weeks, for up to 6 times in total * Visit a doctor's office on a regular basis for checkups and tests
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-11; most recent amendment 2026-03-12.
Status change: Not Yet Recruiting → Recruiting 2025-12-12
Trial Details
NCT Number NCT07076550
Lead Sponsor Alpha-9 Oncology USA Inc.
Conditions Melanoma Metastatic, Uveal Melanoma, Metastatic, Mucosal Melanoma
Enrollment 50 participants
Start Date 2025-11-19
Primary Completion 2028-01 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-16